Last week, pharmaceutical giant Eli Lilly (LLY 1.39%) announced that its cancer drug candidate enzastaurin failed its late-stage clinical trial. Despite this news, shares remained practically flat following the announcement. Was this drug central to Lilly's pipeline, or was it one of many oncology drugs that the company is testing? Should investors instead be worried about Lilly's upcoming patent expirations? What about the ever-present competition from diabetes powerhouse Novo Nordisk (NVO 1.89%)? Health-care analyst Max Macaluso discusses these topics in the following video.
What Does This Failure Mean for Eli Lilly Investors?
By Max Macaluso – May 13, 2013 at 6:30PM
NYSE: LLY
Eli Lilly
Market Cap
$886B
Today's Change
(-1.39%) $13.07
Current Price
$924.37
Price as of November 7, 2025 at 4:00 PM ET
Eli Lilly announced that it will stop developing cancer drug candidate enzastaurin. What does this mean for its business?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo